UBS O'Connor’s BridgeBio Pharma BBIO Stock Holding History

UBS O'Connor’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-36,000	Closed	-$126K	–	572
2023 Q2	$126K	Sell	36,000 -14,000	-28%	-$211K	﹤0.01%	488
2023 Q1	$10K	Buy	+50,000	New	+$583K	﹤0.01%	593

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's BBIO Position: Q3 2025 in Review

UBS O'Connor sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 13,771 shares — an estimated $595K sold.

UBS O'Connor first reported a position in BBIO in Q3 2023 and held it in 7 quarters. The position peaked at $1.68M in Q4 2024. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

UBS O'Connor reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 13,771 BridgeBio Pharma shares in Q3 2025, an estimated $595K.
UBS O'Connor first reported a position in BridgeBio Pharma in Q3 2023 and held it in 7 quarters.
UBS O'Connor's BridgeBio Pharma position peaked at $1.68M in Q4 2024.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.